Document is current
Any future updates will be listed below
-
Authors
Xiao, Ling
De Jesus, Dario F. https://orcid.org/0000-0001-8826-9095
Ju, Cheng-Wei https://orcid.org/0000-0002-2250-8548
Wei, Jiang-Bo https://orcid.org/0000-0003-2691-6490
Hu, Jiang
DiStefano-Forti, Ava
Gonzales, Valeria Salerno
Tsuji, Tadataka https://orcid.org/0000-0002-2837-8246
Wei, Siying
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Tseng, Yu-Hua https://orcid.org/0000-0003-2053-9559
He, Chuan https://orcid.org/0000-0003-4319-7424
Kulkarni, Rohit N. https://orcid.org/0000-0001-5029-6119
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 DK67536)
U.S. Department of Health & Human Services | National Institutes of Health (RC2 DK139552)
U.S. Department of Health & Human Services | National Institutes of Health (UC4 DK116278)
U.S. Department of Health & Human Services | National Institutes of Health (RM1 HG008935)
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 20 December 2024
First Online: 9 January 2025
Competing interests
: R.N.K. is on the scientific advisory board of Novo Nordisk, Biomea and REDD. C.H. is a scientific founder and a member of the scientific advisory board of Accent Therapeutics. M.B. received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, and Sanofi. The remaining authors have no conflicts of interest.
